Skip to Content

MYLAN 2250 MYLAN 2250 (Mycophenolate mofetil 250 mg)

Pill imprint MYLAN 2250 MYLAN 2250 has been identified as Mycophenolate mofetil 250 mg.

Mycophenolate mofetil is used in the treatment of nephrotic syndrome; dermatomyositis; organ transplant, rejection prophylaxis; myasthenia gravis; autoimmune hepatitis (and more), and belongs to the drug class selective immunosuppressants. There is positive evidence of human fetal risk during pregnancy. Mycophenolate mofetil 250 mg is not a controlled substance under the Controlled Substance Act (CSA).

Mycophenolate mofetil 250 mg MYLAN 2250 MYLAN 2250
Mycophenolate mofetil 250 mg MYLAN 2250 MYLAN 2250
Mycophenolate mofetil 250 mg MYLAN 2250 MYLAN 2250
Mycophenolate mofetil
Imprint:
MYLAN 2250 MYLAN 2250
Strength:
250 mg
Color:
Tan / Purple
Size:
19.00 mm
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Selective immunosuppressants
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Manufacturer:
Mylan Pharmaceuticals Inc.
National Drug Code (NDC):
00378-2250
Inactive Ingredients:
silicon dioxide
croscarmellose sodium
magnesium stearate
microcrystalline cellulose
corn starch
sodium lauryl sulfate
ferrosoferric oxide
FD&C Blue No. 2
gelatin
ferric oxide red
titanium dioxide
ferric oxide yellow
ammonia
propylene glycol
shellac
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
51079-0721 UDL Laboratories Inc

Note: Inactive ingredients may vary.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide